An interventional study of Coronary Artery Calcification Realization in Type 1 Diabetes and Coronary Artery Calcification, sponsored by Poitiers University Hospital. Completed at 1 site in France. Open to participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Poitiers University Hospital · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 271 studies in Diabetes Mellitus, Type 1 with a site in France — 39 open to participants now, 45 under way, 8 of them phase 3. Diabetes Mellitus, Type 1 · France.
Among the 271 studies in Diabetes Mellitus, Type 1 with a site in France, this one is the 81st largest by enrollment of the 193 interventional ones that give a count, is one of 14 that started in 2022, is one of 103 with no phase, and was the 208th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →39 of the 271 studies in Diabetes Mellitus, Type 1 with a site in France are open now. Recruiting first, the newest first:
Insulet Corporation · Sites in France
Ages 2+
Sanofi · Sites in France, Belgium, Germany and 3 more countries
Tandem Diabetes Care, Inc. · Sites in France
Ages 6+
Eli Lilly and Company · Sites in France, United States, Australia and 17 more countries
Ages 1–35
Eli Lilly and Company · Sites in France, United States, Australia and 16 more countries
Ages 1–35
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 18 Years to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
271 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 25 · Phase 3 55 · Phase 4 7
First in 2000; this study’s year is marked. 14 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 91 is above the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 67 across the 193 interventional studies, 153 across the 78 observational. Of the 205 that completed or were terminated, 48 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
90 of 271 have an industry lead sponsor. The 10 most frequent:
Poitiers University Hospital is the lead sponsor of 315 studies on the registry; 63 are open to participants now.
Poitiers University Hospital has 3 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
17 of the studies in Diabetes Mellitus, Type 1 with a site in France that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT04583462Phase 3Assistance Publique - Hôpitaux de ParisImpact of Metformin on Peripheral Arterial Calcification in Type 1 Diabetes | 2027-09-29 |
| NCT07457580SanofiReal-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) | 2026-11-30 |
| NCT05221359DefymedPilot Study Evaluating Safety of ExOlin® in Patients With Poorly Controlled Type 1 Diabetes | 2026-12 |
Add all 17 to your calendar (.ics) → With an account.
Among the 271 studies in Diabetes Mellitus, Type 1 with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the study is to compare ESC recommendations on cardiovascular (CV) risk stratification with the achievement of a CAC (Coronary Artery Calcification).
The development of a CAC, currently not systematically offered to these patients to refine CV risk, could make it possible to offer more intensive management of CV risk facors for patients who objectively have a high CV risk as evidenced by a high coronary calcium score.
LDL target recommandations have become more aggressive with a very high level of evidence in type 2 diabetic patients but low in type 1 diabetic patients because there is no specific CV intervention study for T1D patients.
These recommendations have far-reaching consequences because they would justify introducing in young type 1 diabetic patients, considered from the outset to be at moderate cardiovascular risk (young T1DM \<35 years old) or even at high cardiovascular risk (duration of diabetes > 10 years) or very high cardiovascular risk (duration of diabetes > 20 years), treatment with statins or even aspirin, based only on the length of time they have had diabetes.
The realization of a CAC, currently not systematically offered to these patients to refine CV risk, could make it possible to propose a more intensive management of CV risk factors for patients with objectively high CV risk attested by a high coronary calcium score.
In this case the introduction of treatment with statins would be indicated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic Test: Coronary Artery Calcification Realization
Coronary Artery Calcification Realization
Change of Statin Prescription Indication Between Consensus of the French Society of Cardiology and the French Speaking Society of Diabetology 2020 and the ESC/EASD Consensus
Patients for whom the indication for prescribing statins for primary prevention would change if the CAC score were used as a diagnostic tool for cardiovascular risk instead of the 2019 ESC/EASD guidelines in patients with type 1 diabetes aged 18 to 35.
Time frame: 1 day
| Milestone | Coronary Artery Calcification Evaluation |
|---|---|
| Started | 91 |
| Completed | 85 |
| Not completed | 6 |
Patients for whom the indication for prescribing statins for primary prevention would change if the CAC score were used as a diagnostic tool for cardiovascular risk instead of the 2019 ESC/EASD guidelines in patients with type 1 diabetes aged 18 to 35.
| Participants | Change of Statin Prescription Indication Between Consensus of the French Society of Cardiology and t |
|---|---|
| Change of Statin Prescription Indication Between Consensus of the French Society of Cardiology and the French Speaking Society of Diabetology 2020 and the ESC/EASD Consensus | 32 |
Collected over 1 day. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Coronary Artery Calcification Evaluation | 0/91 (0%) | 0/91 (0%) | 0/91 (0%) |
Patients with available primary outcome measures.
| Age, Continuous(year) | Coronary Artery Calcification Evaluation |
|---|---|
| Mean | 24.5 ± 4.4 |
| Sex: Female, Male(Participants) | Coronary Artery Calcification Evaluation |
|---|---|
| Female | 44 |
| Male | 41 |
| Race and Ethnicity Not Collected(Participants) | Coronary Artery Calcification Evaluation |
|---|
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2022 to primary completion in Mar 2025, 36 months.
Results were first posted in Oct 2026, 1 year 6 months after primary completion.
Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's 36 months is above that.
Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Poitiers University Hospital →